EXHIBIT 4.3



 


EXHIBIT
4.3


 


THIS
WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
NO REGISTRATION OF TRANSFER OF THIS WARRANT OR THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF WILL BE MADE ON THE BOOKS OF THE
ISSUER UNLESS SUCH TRANSFER IS MADE IN CONNECTION WITH AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR PURSUANT TO AN EXEMPTION
FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT OR SUCH ACT DOES NOT APPLY.


 


COMMON
STOCK PURCHASE WARRANT


(10-YEAR
WARRANT)


 


SYNERGY
STRIPS CORP.


 


	Warrant
    Shares: 3,584,759	Issue
    Date: January 22, 2015



 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for
value received, Knight Therapeutics (Barbados) Inc. (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth in this Warrant, at any time
on or after the date hereof (the “Issue Date”) and on or prior to
the close of business on the tenth anniversary following the Issue Date (the “Termination
Date”) but not thereafter, to subscribe for and purchase from Synergy Strips Corp, a Nevada corporation (the
“Company”), up to 3,584,759 fully paid and nonassessable shares (as
subject to adjustment hereunder, the “Warrant Shares”) of the Company’s
Common Stock (the “Common Stock”), represent 5% of the Company’s
Common Stock on a Fully Diluted Basis. The purchase price of one share of Common Stock under this Warrant is equal to the Exercise
Price, as defined in Section 1(b).


 


Notwithstanding
the foregoing, in the event that the Closing Price of the Common Stock should remain at or above $1.00 for six (6) consecutive
months (the “Benchmark Period”), the Holder shall forfeit the difference between the number of (i) Warrant Shares
acquired under this Warrant prior to the expiry of the ninety (90) days after the Benchmark Period and (ii) 25% of the Warrant
Shares purchasable hereunder.


 


Section
1. Exercise.


 


(a)
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after
the Issue Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company
as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company)
of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto. Except for cashless exercises pursuant to Section
1(c) below, on the date of exercise, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable
Notice of Exercise by wire transfer or cashier’s check drawn on a United States or Canadian chartered bank. Notwithstanding
anything herein to the contrary, the Holder is not required to physically surrender this Warrant to the Company until the Holder
has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case the Holder
shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice
of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number
of Warrant Shares available hereunder will have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder
in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of
Exercise Form within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount
stated on the face hereof.


 




    	 



    	 



    


 


(b)
Exercise Price. The exercise price per share of the Common Stock under this Warrant
is $0.34, subject to adjustment hereunder (the “Exercise Price”).


 


(c)
Cashless Exercise. Upon the prior written approval of the Company, which approval
may be withheld or conditioned in its sole discretion, this Warrant may be exercised, in whole or in part, by means of a “cashless
exercise” in which the Holder will be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing
[(A-B) (X)] by (A), where:


 


	 	(A)	=	the
                                         Closing Price on the Trading Day immediately preceding the date on which Holder elects
                                         to exercise this Warrant by means of a “cashless exercise,” as set forth
                                         in the applicable Notice of Exercise;



 


	 	(B)	=	the
                                         Exercise Price of this Warrant, as adjusted hereunder; and



 


	 	(X)	=	the
                                         number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance
                                         with the terms of this Warrant if such exercise were by means of a cash exercise rather
                                         than a cashless exercise.



 


		(d)	Mechanics
                                         of Exercise.



 


i.
Delivery of Warrant Shares Upon Exercise. The Company shall use best efforts to
cause the Warrant Shares purchased hereunder to be issued in book-entry format on the records of the transfer agent and registrar
of the Company, or, if the Warrant Shares cannot be issued in book-entry format, then by physical delivery of a stock certificate
to the address specified by the Holder in the Notice of Exercise, by the date that is three (3) Trading Days after the latest
of (A) the delivery to the Company of the Notice of Exercise, (B) surrender of this Warrant (if required) and (C) payment of the
aggregate Exercise Price as set forth above (including by cashless exercise, if permitted) (such date, the “Warrant
Share Delivery Date”). The Warrant Shares will be deemed to have been issued, and the Holder or any other person
so designated to be named therein will be deemed to have become a holder of record of such shares for all purposes, as of the
date on which the Warrant has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted)
and all taxes required to be paid by the Holder, if any, pursuant to Section l(d)(iv) prior to the issuance of such shares having
been paid.


 




    	2



    	 



    


 


ii.
Delivery of New Warrants Upon Exercise. If this Warrant is exercised in part,
the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant
Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called
for by this Warrant, which new Warrant will be, in all other respects, identical with this Warrant.


 


iii.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional
shares may be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled
to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction
in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.


 


iv.
Charges. Taxes and Expenses. Issuance of Warrant Shares will be made without charge
to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all
of which taxes and expenses will be paid by the Company, and such Warrant Shares will be issued in the name of the Holder or in
such name or names as may be directed by the Holder; provided, however, that in
the event Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise
must be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer
Agent fees required for same-day processing of any Notice of Exercise.


 


Section
2. Certain Adjustments.


 


(a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is
outstanding: (i) declares or pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common
Stock or any other equity or equity- equivalent securities payable in shares of Common Stock (which, for avoidance of doubt. does
not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares
of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of
Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital
stock of the Company, then in each case the Exercise Price will be multiplied by a fraction, the numerator of which is the number
of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and the denominator of
which is the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon
exercise of this Warrant will be proportionately adjusted such that the aggregate Exercise Price of all shares of Common Stock
for which this Warrant is then exercisable remains unchanged. Any adjustment made pursuant to this Section 2(a) will become effective
immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and
will become effective immediately after the effective date in the case of a subdivision, combination or re-classification.


 




    	3



    	 



    


 


(b)
Fundamental Transaction. The Company may not enter into or be a party to a Fundamental
Transaction unless the Successor Entity makes appropriate provision for the continuation of this Warrant by either assumption
of this Warrant or by substitution of this Warrant with an equivalent right, in either case pursuant to written agreements in
form and substance satisfactory to the Holder and approved by the Holder prior to such Fundamental Transaction, such approval
not to be unreasonably withheld, conditioned or delayed.


 


(c)
Calculations. No adjustment in the number of Warrant Shares purchasable hereunder
is required unless such adjustment would result in an increase or decrease of at least 0.1% of the number of Warrant Shares for
which this Warrant is exercisable; provided that any adjustments which by reason
of this Section 2(c) are not required to be made will be carried forward and taken into account in any subsequent adjustment.
All calculations under this Section 3 shall be made to the nearest cent or the nearest l/1000th of a share, as the case may be.
For purposes of this Section 2, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding on a Fully Diluted
Basis.


 


(d)
Notice to Holder.


 




i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant
to any provision of this Section 2, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price after
such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts
requiring such adjustment.


 




    	4



    	 



    


 


ii.
Notice to Allow Exercise bv Holder. If (A) the Company declares or pays a dividend
(or any other distribution in whatever form) on the Common Stock, (B) the Company declares or pays a special nonrecurring cash
dividend on or a redemption of the Common Stock, (C) the Company authorizes the granting to all holders of the Common Stock rights
or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders
of the Company is required in connection with any Fundamental Transaction, or (E) the Company authorizes the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed
to the Holder at its last address as it appears upon the Warrant Register of the Company, at least five calendar days prior to
the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken
for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined, or (y) the date on which such Fundamental Transaction is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common
Stock for securities, cash or other property deliverable upon such Fundamental Transaction; provided that the failure to mail
such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to
be specified in such notice. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date
of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.


 


Section
3. Transfer of Warrant.


 


(a)
Transferability. This Warrant and all rights hereunder are transferable, in whole
or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and
funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such
payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The Warrant, if properly
assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant
issued.


 




    	5



    	 



    


 


(b)
Transfer to Comply with the Securities Act. This Warrant may not be exercised,
and neither this Warrant nor any of the Warrant Shares may be disposed of, in whole or in part, except in compliance with applicable
United States federal and state securities or “blue sky” laws and the terms and conditions hereof. Any new Warrant
issued upon transfer of this Warrant will bear a legend in substantially the same form as the legend set forth on the first page
of this Warrant, unless the Holder delivers to the Company an opinion of counsel reasonably satisfactory to the Company that such
new Warrant need no longer be subject to the restriction contained herein. Each certificate for Warrant Shares issued upon exercise
of this Warrant (or subsequently issued in substitution or exchange for such Warrant Shares), unless either (i) at the time of
exercise such Warrant Shares are registered under the Securities Act of 1933, as amended (the “Securities
Act”), or (ii) the Warrant Shares are no longer subject to the restriction contained herein, will bear a legend
substantially in the following form:


 


THE
SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO REGISTRATION
OF TRANSFER OF SUCH SECURITIES WILL BE MADE ON THE BOOKS OF THE ISSUER UNLESS SUCH TRANSFER IS MADE IN CONNECTION WITH AN EFFECTIVE
REGISTRATION STATEMENT UNDER SUCH ACT OR PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT OR SUCH ACT DOES
NOT APPLY.


 


(c)
The provisions of this Section 3 are binding upon all subsequent holders of certificates for Warrant Shares bearing the above
legend and all subsequent holders of this Warrant, if any.


 


(d)
New Warrants. This Warrant may be divided or combined with other Warrants upon
presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations
in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 3(a),
as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant
or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued
on transfers or exchanges will be dated the Issue Date and will be identical to this Warrant except as to the number of Warrant
Shares issuable pursuant thereto.


 


(e)
Warrant Register. The Company shall register this Warrant, upon records to be
maintained by the Company for that purpose (the “Warrant Register”L
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant
as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes,
absent actual notice to the contrary.


 


Section
4. Definitions.
For purposes of this Warrant, the following capitalized terms have the meanings specified in this Section
4:


 


(a)
“Business Day” means a day other than Saturday, Sunday, or any other
day on which commercial banks in New York, New York are authorized or required to by law to close.


 




    	6



    	 



    


 


(b)
“Closing Price” means, for any date, the price determined by the first
of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the closing price
of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed
or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City
time)), (b) if the OTC Bulletin Board is not a Trading Market, the closing price of the Common Stock for such date (or the nearest
preceding date) on the OTC Bulletin Board, (c) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin
Board and if prices for the Common Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc.
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of
the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by a majority
of the independent directors of the Company in their reasonable good faith judgment.


 


(c)
A “Fully-Diluted Basis” means the number of shares of Common Stock outstanding at a given time plus that number of
shares of Common Stock that are issuable upon the conversion, exercise or exchange of all securities of the Company that are convertible
or exchangeable or exercisable into shares of Common Stock based on the applicable conversion, exchange or exercise rate, including
any warrants and any options to purchase shares of Common Stock granted by the Company.


 


(d)
A “Fundamental Transaction” occurs if (i) the Company, directly or
indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person,
(ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition
of all or substantially all of its assets in one or a series of related transactions, (iii) any direct or indirect purchase offer,
tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock
are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders
of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company,
directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another
Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock
(not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated
with the other Persons making or party to, such stock or share purchase agreement or other business combination).


 


(e)
“Person” means an individual, a limited liability company, a partnership,
a joint venture, a corporation, a trust, an unincorporated organization, any other entity or a government or any department or
agency thereof.


 




    	7



    	 



    


 


(f)
“Successor Entity” means the Person formed by, resulting from or surviving
any Fundamental Transaction or the Person with which such Fundamental Transaction has been entered into.


 


(g)
“Trading Dav” means a day on which the principal Trading Market is
open for trading.


 


(h)
“Trading Market” means any of the following markets or exchanges on
which the Common Stock is listed or quoted for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq
Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or the OTC Bulletin Board (or any successors to any
of the foregoing).


 


Section
5. Miscellaneous.


 


(a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder
to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section
1, except as expressly set forth in Section 2.


 


(b)
Loss. Theft. Destruction or Mutilation of Warrant. The Company covenants that
upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant
or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to it, and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor, in lieu of such Warrant or stock certificate.


 


(c)
Saturdays. Sundays. Holidays, etc. If the last or appointed day for the taking
of any action or the expiration of any right required or granted herein is not a Business Day, then such action may be taken or
such right may be exercised on the next succeeding Business Day.


 


(d)
Authorized Shares.


 




The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. If at any time the number of authorized but unissued shares of Common Stock is not sufficient to effect in
full the exercise of this Warrant, in addition to such other remedies as are available to the Holder, the Company will promptly
take such corporate action as may, in the opinion of its counsel, be necessary to increase the number of authorized but unissued
shares of Common Stock to such number of shares as are sufficient for such purposes, including, without limitation, using its
best efforts to obtain the requisite shareholder approval necessary to increase the number of authorized shares of Common Stock.
The Company further covenants that its issuance of this Warrant constitutes full authority to its officers who are charged with
the duty of executing stock certificates to execute and issue the necessary Warrant Shares upon the exercise of the purchase rights
under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may
be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market
upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise
of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and
payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free
from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).


 




    	8



    	 



    

 


Except
and to the extent as waived or consented to by the Holder, the Company may not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue
or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.


 


Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations thereof, exemptions therefor, or consents thereto as may
be necessary from any public regulatory body or bodies having jurisdiction thereof.


 


(e)
Jurisdiction. The validity, interpretation, construction and performance of this
Warrant, and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto, shall be governed,
construed and interpreted in accordance with the laws of the state of New York.


 


(f)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise
any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights,
powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply
with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such
amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees,
including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise
enforcing any of its rights, powers or remedies hereunder.


 


(g)
Notices. Any notice, consent or report required or permitted to be given or made
under this Warrant by one Party to the other Party will be in writing, delivered personally or by U S. first class mail or express
courier providing evidence of receipt, postage prepaid (where applicable), or by electronic mail, to the address set forth on
the signature page hereto. All such notices will be effective upon receipt.


 




    	9



    	 



    


 


(h)
Limitation of Liability. No provision hereof, in the absence of any affirmative
action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges
of the Holder, will give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of
the Company, whether such liability is asserted by the Company or by creditors of the Company.


 


(i)
Remedies. The Holder, in addition to being entitled to exercise all rights granted
by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company
agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions
of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy
at law would be adequate.


 


(j)
Successors and Assigns. Subject to applicable securities laws, this Warrant and
the rights and obligations evidenced hereby will inure to the benefit of and be binding upon the successors and permitted assigns
of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit
of any Holder from time to time of this Warrant and are enforceable by the Holder or any holder of Warrant Shares.


 


(k)
Amendment. This Warrant may be modified or amended or the provisions hereof waived
with the written consent of the Company and the Holder.


 


(l)
Severability. Wherever possible, each provision of this Warrant must be interpreted
in such manner as to be effective and valid under applicable law, but if any provision of this Warrant is prohibited by or invalid
under applicable law, such provision will be ineffective to the extent of such prohibition or invalidity, without invalidating
the remainder of such provisions or the remaining provisions of this Warrant.


 


(m)
Headings. The headings used in this Warrant are for the convenience of reference
only and shall not, for any purpose, be deemed a part of this Warrant.


 


(Signature
Page Follows)


 




    	10



    	 



    


 


IN
WITNESS WHEREOF, each of the Company and the Holder has caused this Warrant to be executed as of the date first above indicated.


 


	 	KNIGHT
    THERAPEUTICS (BARBADOS) INC.
	 	 
	 	By:	/s/
    Andrew C. Ferreira
	 	Name:	Andrew C. Ferreira
	 	Title:	Director
	 	Address:	Chancery House,
    High Street, Bridgetown, St.

    Michael, BB11128, Barbados, WI



 

	 	With
    a copy to:
	 	 
	 	Davies Ward Phillips
    & Vineberg LLP
	 	900 Third Avenue,
    24lh Floor New York,
	 	NY 10022 Attention:
    Hillel W. Rosen



 



    	 



    	 



    


 


IN
WITNESS WHEREOF, each of the Company and the Holder has caused this Warrant to be executed as of the date first above indicated,


 


	 	SYNERGY
    STRIPS CORP.
	 	 
	 	By:	/s/
    Jack Ross
	 	Name:	Jack Ross
	 	Title:	CEO
	 	Address:	 
	 	 	Attn: President



 



    	 



    	 



    


 


NOTICE
OF EXERCISE


 


TO:
SYNERGY STRIPS CORP.


 


(1)
The undersigned hereby elects to purchase________________ Warrant Shares of the Company pursuant to the terms of the attached
Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable
transfer taxes, if any.


 


(2)
Payment shall take the form of (check applicable box):


 


[  ]
in lawful money of the United States; or


 


[  ]
if permitted, the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
1(c) of the Warrant, to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the
“cashless exercise” procedure set forth in such subsection 1(c).


 


(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:


 


The
Warrant Shares shall be delivered as follows:


 


SIGNATURE
OF HOLDER


 


If
an Individual (Print Name):__________________________________ 


 


If
an Entity (Print Name of Investing Entity):______________________



 


Signature
of Authorized Signatory of Investing Entity:


 


Name
of Authorized Signatory:


 


Title
of Authorized Signatory:


 


Date:____________________________________________________



 




    	 



    	 



    


 


ASSIGNMENT
FORM


 


(To
assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)


 


FOR
VALUE RECEIVED, ________________ shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to


 


	 	 	whose
                                         address is
	 	 
	 	Dated:



 


	 	Holder’s Signature:	 
	 	 	 
	 	Holder’s Address:	 



 


Signature
Guaranteed:


 


NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration
or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those
acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.